Form 4: Tandem Diabetes Care EVP & CCO Mark Novara Receives Significant Equity Awards

Tandem Diabetes Care's Executive Vice President and Chief Commercial Officer, Mark Novara, was granted substantial performance and restricted stock units as part of the company's long-term incentive plan.

Summary

• Mark David Novara, EVP & Chief Commercial Officer of Tandem Diabetes Care Inc. (TNDM), reported new equity awards on May 30, 2025.
• He was awarded 31,486 Performance Stock Units (PSUs) and 31,488 Restricted Stock Units (RSUs) under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan.
• Each PSU represents a contingent right to receive one share of common stock, with the number of shares issued potentially ranging from 0% to 200% based on company performance metrics as of December 31, 2027, and continued service.
• Each RSU represents a contingent right to receive one share of common stock or cash, with 33% vesting on May 15, 2026, and the remainder vesting in eight equal quarterly installments thereafter.
• Following these awards, Mr. Novara beneficially owns 25,195 shares of common stock directly, in addition to the newly acquired derivative securities.

Sentiment

Score: 7

Explanation: The document reports routine executive equity compensation, which is generally positive as it aligns management incentives with shareholder value, but it does not contain new financial performance data or strategic announcements that would significantly alter the company's outlook.

Positives

• The granting of significant equity awards to a key executive like Mark Novara aligns management's long-term interests directly with shareholder value.
• Performance Stock Units (PSUs) are tied to pre-defined company performance metrics, incentivizing the executive to achieve specific strategic and financial goals.
• The awards are part of a structured 2023 Long-Term Incentive Plan, indicating a formal approach to executive compensation and retention.

Risks

• The actual number of shares received from Performance Stock Units (PSUs) can range from 0% to 200% of the awarded amount, meaning the executive may receive no shares if minimum performance metrics are not met by December 31, 2027.
• The vesting of both PSUs and RSUs is contingent on the awardee's continuing service, posing a risk of forfeiture if employment ceases.

Future Outlook

The future outlook for the awarded equity is tied to the achievement of pre-defined company performance metrics by December 31, 2027, for PSUs, and a multi-year vesting schedule for RSUs extending beyond May 2026.

Management Comments

• The awards were granted pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto.

Industry Context

The granting of performance-based and time-based equity awards to key executives is a common practice in the medical device and biotechnology industries, aimed at incentivizing long-term performance, retaining talent, and aligning management's interests with those of shareholders.

Comparison to Industry Standards

• The use of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice across the healthcare and technology sectors, including companies like Medtronic, Dexcom, and Insulet, which also utilize similar long-term incentive structures to motivate and retain key personnel.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity awards align the interests of a key executive with shareholders by tying a significant portion of their compensation to the company's long-term performance and stock value.
• Employees: The long-term incentive plan can serve as a model for broader employee incentive programs, potentially boosting morale and retention across the organization.

Next Steps

• Vesting of Restricted Stock Units (RSUs) will commence on May 15, 2026, and continue quarterly thereafter.
• Performance Stock Units (PSUs) will be measured against pre-defined company performance metrics as of December 31, 2027, to determine the final number of shares to be issued.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Transaction, Executive Compensation, Performance Stock Unit, Restricted Stock Unit, Equity Award, Long-Term Incentive Plan, Mark Novara